Upstream Bio, Inc. (UPB) Insider Trading
Over the last 3 months, UPB insiders made 0 open-market buys and 5 sales, a net sale of -$31K (SEC Form 4). Over the last 6 months, 98 institutions increased and 68 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
5
Net (3m)
-$30.6K
Insider trades by month Buys Sells
Mar
Jun
Context3-month price -23.1%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 17, 2026 | Ambrose Allisonofficer: General Counsel | Sell | 477 | $6.10 |
| Jun 17, 2026 | Deykin Aaronofficer: Chief Medical Officer | Sell | 895 | $6.10 |
| Jun 17, 2026 | Houghton Adamofficer: Chief Business Officer | Sell | 700 | $6.10 |
| Jun 17, 2026 | Sutherland Everett Randdirector, officer: Chief Executive Officer | Sell | 2,095 | $6.10 |
| Jun 17, 2026 | GRAY MICHAELofficer: CFO and COO | Sell | 853 | $6.10 |
| Jun 11, 2026 | Ruddy Marcella K.director | Grant | 17,096 | $6.69 |
| Jun 11, 2026 | Renaud Ronald C JRdirector | Grant | 17,096 | $6.69 |
| Jun 11, 2026 | Chimovits Erezdirector | Grant | 17,096 | $6.69 |
| Jun 11, 2026 | Ratcliffe Liamdirector | Grant | 17,096 | $6.69 |
| Jun 11, 2026 | Beckman Danielladirector | Grant | 17,096 | $6.69 |
| Jun 11, 2026 | Fleming Harold Edwarddirector | Grant | 17,096 | $6.69 |
| Mar 17, 2026 | GRAY MICHAELofficer: CFO and COO | Sell | 852 | $9.29 |
| Mar 17, 2026 | Deykin Aaronofficer: Chief Medical Officer | Sell | 894 | $9.29 |
| Mar 17, 2026 | Sutherland Everett Randdirector, officer: Chief Executive Officer | Sell | 2,093 | $9.29 |
| Mar 17, 2026 | Ambrose Allisonofficer: General Counsel | Sell | 475 | $9.29 |
| Mar 17, 2026 | Houghton Adamofficer: Chief Business Officer | Sell | 699 | $9.29 |
| Jan 6, 2026 | GRAY MICHAELofficer: CFO and COO | Grant | 91,500 | $27.07 |
| Jan 6, 2026 | Ambrose Allisonofficer: General Counsel | Grant | 51,000 | $27.07 |
| Jan 6, 2026 | Deykin Aaronofficer: Chief Medical Officer | Grant | 32,000 | — |
| Jan 6, 2026 | Deykin Aaronofficer: Chief Medical Officer | Grant | 96,000 | $27.07 |
| Jan 6, 2026 | GRAY MICHAELofficer: CFO and COO | Grant | 30,500 | — |
| Jan 6, 2026 | Sutherland Everett Randdirector, officer: Chief Executive Officer | Grant | 75,000 | — |
| Jan 6, 2026 | Sutherland Everett Randdirector, officer: Chief Executive Officer | Grant | 225,000 | $27.07 |
| Jan 6, 2026 | Houghton Adamofficer: Chief Business Officer | Grant | 25,000 | — |
| Jan 6, 2026 | Houghton Adamofficer: Chief Business Officer | Grant | 75,000 | $27.07 |
| Jan 6, 2026 | Ambrose Allisonofficer: General Counsel | Grant | 17,000 | — |
| Jun 12, 2025 | Fleming Harold Edwarddirector | Grant | 17,096 | $11.59 |
| Jun 12, 2025 | Chimovits Erezdirector | Grant | 17,096 | $11.59 |
| Jun 12, 2025 | Renaud Ronald C JRdirector | Grant | 17,096 | $11.59 |
| Jun 12, 2025 | Ratcliffe Liamdirector | Grant | 17,096 | $11.59 |
Source: UPB SEC Form 4 filings, latest Jun 17, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their UPB positions over the last 6 months (SEC Form 13F).
Increased
98
New positions
90
Reduced
68
Sold out
47
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 8.1M | May 15, 2026 |
| FMR LLC | Reduced | 7.5M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 5.7M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 5.7M | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3.7M | May 15, 2026 |
| BLACKROCK, INC. | Increased | 3.4M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 3.3M | Feb 12, 2026 |
| DECHENG CAPITAL LLC | Reduced | 3.1M | Feb 12, 2026 |
| NORGES BANK | New Position | 2.9M | Feb 10, 2026 |
| DECHENG CAPITAL LLC | Reduced | 2.7M | May 13, 2026 |
| ENAVATE SCIENCES GP, LLC | Unchanged | 2.5M | Feb 17, 2026 |
| ENAVATE SCIENCES GP, LLC | Unchanged | 2.5M | May 15, 2026 |
| VANGUARD GROUP INC | Reduced | 2.4M | Jan 29, 2026 |
| UBS GROUP AG | Increased | 1.8M | Jan 29, 2026 |
| WOODLINE PARTNERS LP | Increased | 1.7M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.